Back to top
more

Sight Sciences (SGHT)

(Delayed Data from NSDQ)

$5.28 USD

5.28
51,469

+0.14 (2.72%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.29 +0.01 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 37.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences (SGHT) to Expand in Europe With New Launch

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 22.58% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.29% and 5.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

ConforMIS (CFMS) delivered earnings and revenue surprises of -34.85% and 2.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know

The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 44.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy

Sight Sciences, Inc. (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%

The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?

Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q4 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 23.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?

PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.

Will Modest Top-Line Growth Aid Akamai (AKAM) Q3 Earnings?

Akamai (AKAM) is expected to have recorded year-over-year higher third-quarter 2022 revenues driven by growth in its security business.

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -8.51% and 17.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?

Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Why Sight Sciences (SGHT) Might Surprise This Earnings Season

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade

The consensus price target hints at a 121.5% upside potential for Sight Sciences, Inc. (SGHT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Quotient (QTNT) Reports Q1 Loss, Lags Revenue Estimates

Quotient (QTNT) delivered earnings and revenue surprises of -32.14% and 6.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?